As of May 26
| -2.17 / -0.86%|
The 25 analysts offering 12-month price forecasts for Biogen have a median target of 318.00, with a high estimate of 442.00 and a low estimate of 262.00. The median estimate represents a +26.79% increase from the last price of 250.80.
The current consensus among 29 polled investment analysts is to Buy stock in Biogen. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.